Alfacell Corp. (ACEL)

Alfacell Corporation, a development stage company, engages in the discovery and development of therapeutic drugs for the treatment of cancer and other pathological conditions primarily in the United States. The company’s primary drug product candidate, ONCONASE is evaluated in human clinical trials for the treatment of various forms of cancer. It also completed preparing new drug application for unresectable malignant mesothelioma. In addition, the company is conducting a Phase I/II clinical trial for lung cancer and other solid tumors. Alfacell was founded in 1981 and is headquartered in Somerset, New Jersey.

For the fiscal year ended 31 July 2006, Alfacell Corporation's revenues decreased 29% to $107K. Net loss increased 21% to $7.8M. Revenues reflect a decrease in investment income due to lower balances of cash & cash equivalents. Higher loss reflects higher research & development expenses due to an increase in share based compensation expense and higher general & administrative expenses.